Zavzpret Spray
Product Images NDC 0069-3500

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Zavzpret (NDC 0069-3500). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Zavegepant 01)

Chemical structure of zavegepant (ZAVZPRET), depicting the molecular arrangement of the active pharmaceutical ingredient in the product.*

FDA Label Image

Figure 1 (Zavegepant 02)

A line graph comparing percent of subjects achieving pain freedom over time after dose for ZAVZPRET nasal spray 10 mg versus placebo. The x-axis shows time from dose in hours, ranging from 0 to 2 hours, and the y-axis shows percent achieving pain freedom, ranging from 0% to 100%. The ZAVZPRET line shows a gradual increase up to about 24%, while the placebo line increases more slowly up to about 15%.*

FDA Label Image

Figure 2 (Zavegepant 03)

A line graph comparing symptom freedom over time between ZAVZPRET nasal spray 10 mg and placebo. The x-axis shows time in hours from dose (0 to 2 hours), and the y-axis shows percent achieving most bothersome symptom freedom (0% to 100%). ZAVZPRET shows a higher percent of symptom freedom increasing over time compared to placebo.*

FDA Label Image

Figure 3 (Zavegepant 04)

A line graph comparing percent achieving pain freedom over 2 hours after dosing between ZAVZPRET nasal spray 10 mg and placebo. The x-axis represents time in hours post-dose (0 to 2 hours), and the y-axis shows percent achieving pain freedom (0% to 100%). ZAVZPRET shows a gradual increase, reaching approximately 22% at 2 hours, while placebo remains lower, around 16%.*

FDA Label Image

Figure 4 (Zavegepant 05)

A line graph showing the percent of subjects achieving freedom from the most bothersome symptom over time, comparing ZAVZPRET nasal spray 10 mg and placebo. The x-axis represents time in hours from dose (0 to 2 hours) and the y-axis represents the percent symptom freedom (0% to 100%). ZAVZPRET shows higher symptom freedom percentages than placebo across the time points.*

FDA Label Image

Logo (Zavegepant 06)

FDA Label Image

Logo (Zavegepant 07)

FDA Label Image

Figure A (Zavegepant 08)

An instructional diagram showing a nasal spray device labeled with its parts. The spray nozzle is indicated as the portion inserted into the nose, and the plunger is labeled as the part pressed with the thumb. The figure is presented in a simple line drawing style with directional arrows to parts.*

FDA Label Image

Figure B (Zavegepant 09)

Instructional diagram labeled Figure B showing a person holding a tissue over their nose and mouth with both hands. The image likely relates to nasal spray use or administration guidance.*

FDA Label Image

Figure C (Zavegepant 10)

An instructional diagram showing a hand removing a single nasal spray device from an open box containing multiple spray devices. The image emphasizes removing only one device at a time, as indicated by an arrow and text instruction.*

FDA Label Image

Figure D (Zavegepant 11)

An instructional illustration showing a hand holding a ZAVZPRET nasal spray device near a nasal passage, with an arrow indicating the spray direction into the nose. The spray device is labeled with the ZAVZPRET brand, showing it is a zavegepant nasal spray.*

FDA Label Image

Figure E (Zavegepant 12)

Instructional illustration showing two hands opening a blister pack by peeling back the protective foil layer, with the figure labeled as Figure E.*

FDA Label Image

Figure F (Zavegepant 13)

An instructional illustration showing the proper nasal spray technique for ZAVZPRET (zavegepant) nasal spray. The diagram highlights positioning the spray device at the nostril for correct administration.*

FDA Label Image

Figure G (Zavegepant 14)

An instructional illustration showing a hand holding a nasal spray device, with thumb positioned on the bottom to activate the spray. Labeled as Figure G, it demonstrates proper finger placement for using the nasal spray.*

FDA Label Image

Figure H (Zavegepant 15)

Illustration showing a person using their finger to gently press one nostril closed, with an arrow indicating the direction, demonstrating preparation for nasal spray administration.*

FDA Label Image

Figure I (Zavegepant 16)

An instructional illustration showing a person using a nasal spray. The individual is holding the spray device near one nostril while holding the other nostril closed with a finger, demonstrating correct administration technique for a nasal spray product.*

FDA Label Image

Figure J (Zavegepant 17)

An instructional illustration showing how to use the ZAVZPRET nasal spray. It depicts a hand pressing down firmly on the spray plunger inserted into a nostril, accompanied by text prompting the user to press the plunger up firmly while breathing in through the nose.*

FDA Label Image

Figure K (Zavegepant 18)

An instructional illustration showing a person gently breathing in through the nose and out through the mouth. The person is advised to keep their head level and upright while breathing, with a timer highlighting a duration of 10-20 seconds for the breathing cycle.*

FDA Label Image

Figure L (Zavegepant 19)

An instructional illustration labeled Figure L showing a hand disposing of a nasal spray device into a trash receptacle marked 'TRASH' with a green downward arrow indicating the action of discarding the spray.*

FDA Label Image

Logo (Zavegepant 20)

FDA Label Image

Principal Display Panel – Nasal Spray Device Label Front (Zavzpret 07)

Label for ZAVZPRET nasal spray, 10 mg, containing the active ingredient zavegepant. The label includes instructions for intranasal use only and notes the NDC number 0069-3500-01. It states that the product is Rx only and contains a caution not to test spray, but to prime or press the plunger before use. The labeler is Pfizer Laboratories Div Pfizer Inc.*

FDA Label Image

Principal Display Panel – Nasal Spray Device Label Back (Zavzpret 08)

A partial product label for ZAVZPRET nasal spray by Pfizer Labs, Division of Pfizer Inc. The label displays a lot number and expiration date placeholder. The design includes black and pink accents on a white background with minimal text visible.*

FDA Label Image

Principal Display Panel – Nasal Spray Blister Foil Label (Zavzpret 09)

ZAVZPRET (zavegepant) nasal spray 10 mg unit-dose label showing product name, strength, dosage form, and usage instructions. The label includes storage guidelines, a warning to keep out of reach of children, and distributor information for Pfizer Laboratories, Division of Pfizer Inc. The label also features a barcode and a peel-off corner.*

FDA Label Image

Principal Display Panel – Nasal Spray Carton (Zavzpret 10)

Packaging label for ZAVZPRET nasal spray 10 mg (zavegepant) by Pfizer Laboratories Div Pfizer Inc. The box contains six unit-dose nasal spray devices, each delivering 10 mg of zavegepant. The label includes storage instructions, usage notes, NDC 0069-3500, and mentions that the product is for intranasal use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.